CD8A and pelvic inflammatory disease: PID11 displayed a low increase in IFN-γ production (from 0 to 99 mUI/mL) post-vaccine, whereas the other PID patient developed T CD8+ lymphocytopenia (196 cell/uL) after rituximab treatment.